These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 17595753)

  • 21. [CORE study].
    Mizunuma H
    Nihon Rinsho; 2007 Nov; 65 Suppl 9():294-8. PubMed ID: 18161121
    [No Abstract]   [Full Text] [Related]  

  • 22. Apoptotic action of 17beta-estradiol in raloxifene-resistant MCF-7 cells in vitro and in vivo.
    Liu H; Lee ES; Gajdos C; Pearce ST; Chen B; Osipo C; Loweth J; McKian K; De Los Reyes A; Wing L; Jordan VC
    J Natl Cancer Inst; 2003 Nov; 95(21):1586-97. PubMed ID: 14600091
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Influence of the selective oestrogen receptor modulator (raloxifene hydrochloride) on IL-6, TNF-alpha, TGF-beta1 and bone turnover markers in the treatment of postmenopausal osteoporosis.
    Ozmen B; Kirmaz C; Aydin K; Kafesciler SO; Guclu F; Hekimsoy Z
    Eur Cytokine Netw; 2007 Sep; 18(3):148-53. PubMed ID: 17823083
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Inhibition of Fatty Acid Synthase (FASN) synergistically enhances the efficacy of 5-fluorouracil in breast carcinoma cells.
    Vazquez-Martin A; Ropero S; Brunet J; Colomer R; Menendez JA
    Oncol Rep; 2007 Oct; 18(4):973-80. PubMed ID: 17786362
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effects of hormonal therapy on cognitive functioning in breast cancer patients: a review of the literature.
    Schilder CM; Schagen SB
    Minerva Ginecol; 2007 Aug; 59(4):387-401. PubMed ID: 17923830
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The STAR trial: evidence for raloxifene as a breast cancer risk reduction agent for postmenopausal women.
    Bevers TB
    J Natl Compr Canc Netw; 2007 Sep; 5(8):719-24. PubMed ID: 17927929
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Zoledronic acid is unable to induce apoptosis, but slows tumor growth and prolongs survival for non-small-cell lung cancers.
    Li YY; Chang JW; Chou WC; Liaw CC; Wang HM; Huang JS; Wang CH; Yeh KY
    Lung Cancer; 2008 Feb; 59(2):180-91. PubMed ID: 17900752
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Biological evaluation of 2,3-dichloro-5,8-dimethoxy-1,4-naphthoquinone as an anti-breast cancer agent.
    Kanaan YM; Das JR; Bakare O; Enwerem NM; Berhe S; Beyene D; Williams V; Zhou Y; Copeland RL
    Anticancer Res; 2009 Jan; 29(1):191-9. PubMed ID: 19331150
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Rationale for using raloxifene to prevent both osteoporosis and breast cancer in postmenopausal women.
    Lee WL; Chao HT; Cheng MH; Wang PH
    Maturitas; 2008 Jun; 60(2):92-107. PubMed ID: 18534794
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Randomized clinical trials of raloxifene: reducing the risk of osteoporosis and breast cancer in postmenopausal women.
    Olevsky OM; Martino S
    Menopause; 2008; 15(4 Suppl):790-6. PubMed ID: 18596600
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Risks, benefits, and effects on quality of life of selective estrogen-receptor modulator therapy in postmenopausal women at increased risk of breast cancer.
    Ganz PA; Land SR
    Menopause; 2008; 15(4 Suppl):797-803. PubMed ID: 18596601
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effects of raloxifene hydrochloride on endometrial cancer cells in vitro.
    Hibner M; Magrina JF; Lefler SR; Cornella JL; Pizarro AR; Loftus JC
    Gynecol Oncol; 2004 Jun; 93(3):642-6. PubMed ID: 15196858
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Increased antitumor potential of the raloxifene prodrug, raloxifene diphosphate.
    Okamoto Y; Liu X; Suzuki N; Okamoto K; Sekimoto M; Laxmi YR; Shibutani S
    Int J Cancer; 2008 May; 122(9):2142-7. PubMed ID: 18183587
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Apple phytochemical extracts inhibit proliferation of estrogen-dependent and estrogen-independent human breast cancer cells through cell cycle modulation.
    Sun J; Liu RH
    J Agric Food Chem; 2008 Dec; 56(24):11661-7. PubMed ID: 19053381
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Inhibitive effect of 3-bromopyruvic acid on human breast cancer MCF-7 cells involves cell cycle arrest and apoptotic induction.
    Liu XH; Zheng XF; Wang YL
    Chin Med J (Engl); 2009 Jul; 122(14):1681-5. PubMed ID: 19719971
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Can serum estradiol predict the effect of raloxifene on breast cancer risk?].
    von Schoultz E
    Lakartidningen; 2002 May; 99(18):2068. PubMed ID: 12082787
    [No Abstract]   [Full Text] [Related]  

  • 37. Effects of tamoxifen and raloxifene on normal human endometrial cells in an organotypic in vitro model.
    Bläuer M; Heinonen PK; Rovio P; Ylikomi T
    Eur J Pharmacol; 2008 Sep; 592(1-3):13-8. PubMed ID: 18638473
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Estrogen receptor beta increases the efficacy of antiestrogens by effects on apoptosis and cell cycling in breast cancer cells.
    Hodges-Gallagher L; Valentine CD; El Bader S; Kushner PJ
    Breast Cancer Res Treat; 2008 May; 109(2):241-50. PubMed ID: 17638070
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Role of estrogen and selective estrogen receptor modulators in anti-aging].
    Ohta H
    Clin Calcium; 2008 Jul; 18(7):986-94. PubMed ID: 18591752
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Raloxifene in clinical practice. Results of the non-interventional study CORAL (COmpliance with RALoxifene)].
    Rosa J; Vanuga P; Payer J; Svobodník A
    Vnitr Lek; 2008 Mar; 54(3):217-9, 221-4. PubMed ID: 18522288
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.